| May 14, 2012 |
METHYLGENE REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL PROGRAMS |
| April 2, 2012 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING |
| March 28, 2012 |
METHYLGENE TO PRESENT AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING |
| March 19, 2012 |
METHYLGENE ANNOUNCES THE APPOINTMENT OF PEGGY MULLIGAN TO ITS BOARD OF DIRECTORS |
| March 15, 2012 |
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS |
| February 7, 2012 |
METHYLGENE TO PRESENT AT THE 14th ANNUAL BIO CEO & INVESTOR CONFERENCE |
| February 2, 2012 |
METHYLGENE ANNOUNCES THE APPOINTMENT OF DR. HENRY J. FUCHS TO ITS BOARD OF DIRECTORS |
| January 4, 2012 |
METHYLGENE ANNOUNCES THE APPOINTMENT OF RACHEL HUMPHREY, MD AS EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER |
| November 22, 2011 |
MethylGene to Present at the 23rd Annual Piper Jaffray Healthcare Conference |
| November 14, 2011 |
METHYLGENE REPORTS CLINICAL DATA FOR MGCD265 AT THE 2011 AACR-NCI-EORTC MOLECULAR TARGETS AND CANCER THERAPEUTICS CONFERENCE |
| November 3, 2011 |
METHYLGENE REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE |
| October 18, 2011 |
METHYLGENE RECEIVES FDA IND APPROVAL TO BEGIN A PHASE 2 CLINICAL TRIAL WITH MGCD290, A NOVEL ANTIFUNGAL PRODUCT CANDIDATE |
| October 6, 2011 |
METHYLGENE APPOINTS JOSEPH WALEWICZ AS VICE PRESIDENT, BUSINESS AND CORPORATE DEVELOPMENT |
| September 7, 2011 |
METHYLGENE TO PRESENT AT THE RODMAN & RENSHAW 13TH ANNUAL HEALTHCARE CONFERENCE |
| August 11, 2011 |
METHYLGENE REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE |
| June 22, 2011 |
METHYLGENE TO PRESENT AT THE 2011 BIO BUSINESS FORUM |
| June 14, 2011 |
METHYLGENE REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE |
| June 8, 2011 |
METHYLGENE ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS AND FIRST QUARTER 2011 CONFERENCE CALL |
| June 3, 2011 |
METHYLGENE REPORTS CLINICAL DATA FOR MGCD265 AT THE 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING |
| May 25, 2011 |
METHYLGENE TO PRESENT AT BIOFINANCE 2011 CONFERENCE |
| May 19, 2011 |
METHYLGENE TO PRESENT MGCD265 DATA AT THE 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING |
| April 5, 2011 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING |
| April 4, 2011 |
METHYLGENE CLOSES $34.5 MILLION PRIVATE PLACEMENT |
| April 1, 2011 |
METHYLGENE CLOSING PRIVATE PLACEMENT |
| March 30, 2011 |
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2010 FINANCIAL RESULTS |
| March 29, 2011 |
METHYLGENE TO PRESENT MGCD265 DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING |
| March 24, 2011 |
METHYLGENE ANNOUNCES $34.5 MILLION PRIVATE PLACEMENT |
| January 6, 2011 |
METHYLGENE TO PRESENT AT BIOTECH SHOWCASE 2011 |
| December 6, 2010 |
METHYLGENE PRESENTS FAVORABLE CLINICAL DATA FOR MOCETINOSTAT AT THE 52nd AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING |
| November 29, 2010 |
METHYLGENE PRESENTS FAVORABLE CLINICAL DATA FOR MOCETINOSTAT AT THE 52nd AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING |
| November 18, 2010 |
METHYLGENE PRESENTS ENCOURAGING CLINICAL DATA FOR MGCD265 IN SOLID TUMOR CANCERS AT THE 22nd EORTC-NCI-AACR ANNUAL MEETING |
| November 12, 2010 |
METHYLGENE REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE FOR MGCD265 |
| November 10, 2010 |
METHYLGENE TO PRESENT AT THE 22ND EORTC-NCI-AACR SYMPOSIUM |
| October 20, 2010 |
METHYLGENE’S LEAD PROGRAM, MGCD265, NOMINATED “TOP TEN ONCOLOGY PROJECTS TO WATCH” BY WINDHOVER AND CAMPBELL ALLIANCE |
| September 29, 2010 |
METHYLGENE TO PRESENT AT BIOCONTACT QUÉBEC |
| September 28, 2010 |
METHYLGENE ISSUED KEY PATENTS FOR LEAD ONCOLOGY PROGRAM |
| September 16, 2010 |
METHYLGENE ENTERS INTO $15 MILLION EQUITY LINE FACILITY AGREEMENT |
| September 13, 2010 |
METHYLGENE PRESENTS PHASE I DATA FOR ITS NOVEL ANTIFUNGAL AGENT, MGCD290, AT THE 50TH ANNUAL ICAAC MEETING |
| September 13, 2010 |
METHYLGENE ANNOUNCES CHANGES TO SENIOR MANAGEMENT |
| August 31, 2010 |
METHYLGENE APPOINTS DR. MARTIN GODBOUT AS CHAIRMAN OF THE BOARD OF DIRECTORS |
| August 25, 2010 |
METHYLGENE ANNOUNCES CHANGE TO THE BOARD OF DIRECTORS |
| July 30, 2010 |
METHYLGENE REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE FOR MGCD265 |
| June 30, 2010 |
METHYLGENE FUTHER EXTENDS COLLABORATION WITH OTSUKA PHARMACEUTICALS FOR THE DEVELOPMENT OF KINASE INHIBITORS FOR TREATMENT OF OCULAR DISEASES |
| June 7, 2010 |
METHYLGENE PRESENTS CLINICAL DATA FOR MOCETINOSTAT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2010 ANNUAL MEETING |
| May 21, 2010 |
DATA FROM METHYLGENE’S MGCD265 AND MOCETINOSTAT CLINICAL TRIALS TO BE PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING |
| May 19, 2010 |
METHYLGENE ANNOUNCES COMPLETION OF NON-DILUTIVE FINANCING |
| May 14, 2010 |
METHYLGENE SHAREHOLDERS APPROVE NON-DILUTIVE FINANCING OF UP TO $9.1 MILLION AND COMPANY REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS |
| April 29, 2010 |
METHYLGENE TO PRESENT AT THE 2010 BIO BUSINESS FORUM |
| April 23, 2010 |
METHYLGENE ANNOUNCES ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND PROVIDES CORPORATE UPDATE |
| April 20, 2010 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 (A MULTI-TARGETED MET KINASE INHIBITOR) AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING |
| April 16, 2010 |
METHYLGENE TO PRESENT MGCD265 DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING |
| March 26, 2010 |
METHYLGENE ANNOUNCES NON-DILUTIVE FINANCING OF UP TO $8.9 MILLION AND REPORTS FOURTH QUARTER AND FULL YEAR 2009 FINANCIAL RESULTS |
| January 7, 2010 |
METHYLGENE TO PRESENT AT BIOTECH SHOWCASE 2010 |
| November 17, 2009 |
METHYLGENE REPORTS FAVORABLE PHASE I DATA FOR MGCD265 IN SOLID TUMORS AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE |
| November 5, 2009 |
METHYLGENE REPORTS THIRD QUARTER 2009 FINANCIAL RESULTS |
| October 20, 2009 |
METHYLGENE ISSUES SHARES TO OTSUKA PHARMACEUTICAL CO., LTD. |
| October 14, 2009 |
METHYLGENE ANNOUNCES EQUITY INVESTMENT FROM OTSUKA PHARMACEUTICAL CO., LTD. |
| September 21, 2009 |
METHYLGENE TO RESUME DEVELOPMENT OF ITS HDAC INHIBITOR, MGCD0103 (MOCETINOSTAT) |
| September 15, 2009 |
METHYLGENE PRESENTS PHASE I DATA FOR ITS NOVEL ANTIFUNGAL AGENT, MGCD290, AT THE 49TH ANNUAL ICAAC MEETING |
| September 14, 2009 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS BETA-LACTAMASE INHIBITOR, MG96077, AT THE 49TH ANNUAL ICAAC MEETING |
| September 9, 2009 |
METHYLGENE AND OTSUKA PHARMACEUTICAL CO. LTD. EXTEND FUNDED RESEARCH COLLABORATION |
| September 8, 2009 |
METHYLGENE TO PRESENT DATA AT THE 49TH ANNUAL ICAAC MEETING |
| September 2, 2009 |
METHYLGENE INITIATES PHASE II PROGRAM FOR MGCD265 IN SOLID TUMORS AND NON-SMALL CELL LUNG CANCER PATIENTS |
| July 31, 2009 |
METHYLGENE REPORTS SECOND QUARTER 2009 FINANCIAL RESULTS |
| May 29, 2009 |
METHYLGENE ANNOUNCES MANAGEMENT TRANSITION |
| May 28, 2009 |
METHYLGENE REPORTS FAVORABLE PRELIMINARY PHASE I DATA FOR MGCD265, ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, AT ASCO ANNUAL MEETING |
| May 8, 2009 |
METHYLGENE REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS |
| April 23, 2009 |
METHYLGENE ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS |
| April 21, 2009 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS SECOND ORAL KINASE INHIBITOR, MG516, AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING |
| March 30, 2009 |
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2008 FINANCIAL RESULTS |
| March 27, 2009 |
METHYLGENE RESCHEDULES FULL YEAR 2008 CONFERENCE CALL TO APRIL 7TH |
| March 24, 2009 |
METHYLGENE FOURTH QUARTER AND FULL YEAR 2008 RESULTS CONFERENCE CALL NOTICE |
| November 26, 2008 |
METHYLGENE TO PRESENT AT INVESTOR CONFERENCES |
| November 10, 2008 |
METHYLGENE REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS |
| October 27, 2008 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD290, A HOS2 FUNGAL INHIBITOR, AT JOINT ICAAC/IDSA ANNUAL MEETING |
| October 27, 2008 |
METHYLGENE REACQUIRES RIGHTS TO MGCD0103 FROM CELGENE AND IMPLEMENTS STRATEGIC PLAN TO FOCUS ON DEVELOPMENT OF PROPRIETARY CLINICAL PIPELINE |
| October 23, 2008 |
METHYLGENE TO PRESENT AT THE 7th ANNUAL BIO INVESTOR FORUM |
| October 22, 2008 |
METHYLGENE PRESENTS PRECLINICAL BIOMARKER DATA FOR MGCD265 AT THE 20TH EORTC-NCI-AACR SYMPOSIUM |
| October 15, 2008 |
METHYLGENE INITIATES PHASE I CLINICAL STUDY WITH MGCD290 FOR FUNGAL INFECTIONS |
| October 2, 2008 |
METHYLGENE RECEIVES CLINICAL TRIAL APPROVAL FROM HEALTH CANADA FOR ITS PROPRIETARY PRODUCT CANDIDATE MGCD290 FOR FUNGAL INFECTIONS |
| September 19, 2008 |
METHYLGENE EXERCISES RIGHT TO CONVERT MGCD0103 COLLABORATION WITH CELGENE TO PRE-DETERMINED ROYALTY AND MILESTONE ARRANGEMENT |
| August 15, 2008 |
METHYLGENE PROVIDES UPDATE ON SUSPENSION OF NEW ENROLLMENT IN MGCD0103 CLINICAL TRIALS |
| July 30, 2008 |
METHYLGENE REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS |
| July 29, 2008 |
METHYLGENE TO PRESENT AT INVESTOR CONFERENCES |
| July 22, 2008 |
METHYLGENE AND CELGENE ANNOUNCE PRECAUTIONARY SUSPENSION OF NEW ENROLLMENTS INTO MGCD0103 CLINICAL TRIALS |
| June 25, 2008 |
METHYLGENE ANNOUNCES THE INITIATION OF A RANDOMIZED, THREE-ARM PHASE II TRIAL OF MGCD0103 IN COMBINATION WITH VIDAZA(R) IN PATIENTS WITH HIGH-RISK MDS OR AML |
| June 12, 2008 |
METHYLGENE INITIATES SECOND PHASE I CLINICAL TRIAL WITH MGCD265, A MULTI-TARGETED (C-MET) KINASE INHIBITOR IN PATIENTS WITH SOLID TUMORS |
| June 11, 2008 |
METHYLGENE TO PRESENT AT THE 2008 BIO BUSINESS FORUM |
| June 5, 2008 |
METHYLGENE TO PRESENT AT THE 7TH ANNUAL NEEDHAM BIOTECHNOLOGY & MEDICAL TECHNOLOGY CONFERENCE |
| June 3, 2008 |
METHYLGENE REPORTS CLINICAL DATA FROM A PHASE II STUDY EVALUATING MGCD0103 IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING |
| June 2, 2008 |
METHYLGENE REPORTS CLINICAL DATA FOR MGCD0103 AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING |
| May 16, 2008 |
CLINICAL DATA FOR METHYLGENE’S MGCD0103 TO BE PRESENTED AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING |
| May 12, 2008 |
METHYLGENE REPORTS FIRST QUARTER 2008 FINANCIAL RESULTS |
| April 30, 2008 |
METHYLGENE TO PRESENT AT BIOFINANCE 2008 |
| April 16, 2008 |
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, MGCD265, AT AACR ANNUAL MEETING |
| April 16, 2008 |
METHYLGENE INITIATES PHASE I CLINICAL TRIAL FOR ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, MGCD265, IN SOLID TUMOR CANCERS |
| April 15, 2008 |
METHYLGENE PROVIDES UPDATE ON ITS MGCD0103 HDAC INHIBITOR COLLABORATION WITH CELGENE |
| April 14, 2008 |
METHYLGENE PRESENTS CLINICAL BIOMARKER DATA FOR MGCD0103 AND PRECLINICAL EFFICACY DATA IN COMBINATION WITH TAXANES AT AACR ANNUAL MEETING |
| April 4, 2008 |
METHYLGENE ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS AND CORRECTS PREVIOUSLY DISCLOSED INTERIM DATA FOR TRIAL 005 |
| March 27, 2008 |
METHYLGENE ANNOUNCES WORLDWIDE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO. LTD. |
| March 7, 2008 |
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS |
| February 29, 2008 |
METHYLGENE FOURTH QUARTER AND YEAR-END 2007 CONFERENCE CALL NOTICE |
| February 14, 2008 |
METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA |
| February 11, 2008 |
METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA |
| February 6, 2008 |
METHYLGENE EXERCISES RIGHT TO OPT-OUT OF HDAC NEURODEGENERATIVE COLLABORATION WITH ENVIVO |
| February 5, 2008 |
METHYLGENE TO PRESENT AT BIO CEO & INVESTOR CONFERENCE |
| January 28, 2008 |
METHYLGENE REPORTS MGCD0103 CLINICAL DATA AT THE 2008 GASTROINTESTINAL CANCERS SYMPOSIUM |
| January 9, 2008 |
METHYLGENE AND PHARMION START PHASE II COMBINATION CLINICAL TRIAL WITH MGCD0103 AND VIDAZA® IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR NON-HODGKIN LYMPHOMA |
| January 4, 2008 |
METHYLGENE FILES IND FOR MGCD265, MULTI-TARGETED KINASE (C-MET) INHIBITOR FOR ONCOLOGY |